Saturday 17 October 2026
Export ZURA’s income statement to Excel — free account
Zura Bio Limited
ZURA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 23.5% and free cash flow fell 30.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.88
0.40
−9.35%
Follow ZURA
Zura Bio Limited (ZURA) P/E ratio
Zura Bio Limited has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 48.9× (March 2023) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 48.9×
Ten-year median
0.0×
Current reading's percentile
43
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| SPRY ARS Pharmaceuticals, Inc. compare | n/m |
| INDP Indaptus Therapeutics, Inc. compare | n/m |
| TECX Tectonic Therapeutic, Inc. compare | n/m |
| PRTA Prothena Corporation plc compare | n/m |
| PRTCY PureTech Health PLC Sponsored ADR compare | n/m |
| DMAC DiaMedica Therapeutics, Inc. compare | n/m |
| CAPR Capricor Therapeutics, Inc. compare | n/m |
| ZURA Zura Bio Limited | n/m |
| ASMB Assembly Biosciences, Inc. compare | 19.7× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)